{"id":"NCT01130493","sponsor":"Impax Laboratories, LLC","briefTitle":"A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066","officialTitle":"A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2010-05-26","resultsPosted":"2017-09-13","lastUpdate":"2019-10-29"},"enrollment":110,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"IPX066","otherNames":["extended-release carbidopa-levodopa"]},{"type":"DRUG","name":"CLE","otherNames":["carbidopa/levodopa/entacapone"]}],"arms":[{"label":"IPX066-CLE-OLE","type":"OTHER"},{"label":"CLE-IPX066-OLE","type":"OTHER"}],"summary":"This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.","primaryOutcome":{"measure":"Percentage of \"OFF\" Time During Waking Hours","timeFrame":"3 days of data immediately prior to the end of each 2 week treatment period","effectByArm":[{"arm":"IPX066","deltaMin":23.98,"sd":16.242},{"arm":"CLE (Active Comparator)","deltaMin":32.48,"sd":21.917}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["United States","France","Germany","Italy"]},"refs":{"pmids":["30425824"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":91},"commonTop":["Nausea","Dyskinesia","Fall","Insomnia","Vomiting"]}}